Aberrant DNA methylation in multiple myeloma: A major obstacle or an opportunity?
Drug resistance (DR) of cancer cells leading to relapse is a huge problem nowadays to achieve long-lasting cures for cancer patients. This also holds true for the incurable hematological malignancy multiple myeloma (MM), which is characterized by the accumulation of malignant plasma cells in the bon...
Main Authors: | Catharina Muylaert, Lien Ann Van Hemelrijck, Anke Maes, Kim De Veirman, Eline Menu, Karin Vanderkerken, Elke De Bruyne |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-08-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.979569/full |
Similar Items
-
Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
by: Elke De Bruyne, et al.
Published: (2013-04-01) -
Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma
by: Inge Oudaert, et al.
Published: (2022-09-01) -
Dendritic Cell-Based Immunotherapy in Multiple Myeloma: Challenges, Opportunities, and Future Directions
by: Emma Verheye, et al.
Published: (2022-01-01) -
Epigenetic treatment of multiple myeloma mediates tumor intrinsic and extrinsic immunomodulatory effects
by: Lien De Beck, et al.
Published: (2018-10-01) -
The prognostic value and therapeutic targeting of myeloid-derived suppressor cells in hematological cancers
by: Rong Fan, et al.
Published: (2022-10-01)